Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 153 | 2024 | 1551 | 15.150 |
Why?
|
Asparaginase | 37 | 2024 | 240 | 5.560 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 18 | 2023 | 382 | 2.480 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 11 | 2023 | 226 | 2.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 57 | 2024 | 11742 | 2.080 |
Why?
|
Azacitidine | 10 | 2013 | 336 | 1.320 |
Why?
|
Neoplasm, Residual | 16 | 2023 | 1008 | 1.290 |
Why?
|
Antineoplastic Agents | 39 | 2024 | 13639 | 1.250 |
Why?
|
Cranial Irradiation | 11 | 2016 | 390 | 1.220 |
Why?
|
Child | 155 | 2024 | 80153 | 1.070 |
Why?
|
Child, Preschool | 104 | 2024 | 42230 | 1.070 |
Why?
|
Myelodysplastic Syndromes | 17 | 2022 | 1394 | 1.040 |
Why?
|
Polyethylene Glycols | 7 | 2021 | 1189 | 1.030 |
Why?
|
Infant | 85 | 2024 | 36192 | 0.980 |
Why?
|
Doxorubicin | 15 | 2018 | 2224 | 0.980 |
Why?
|
Antimetabolites, Antineoplastic | 10 | 2016 | 646 | 0.980 |
Why?
|
Osteonecrosis | 7 | 2022 | 229 | 0.950 |
Why?
|
Dexamethasone | 12 | 2017 | 1948 | 0.930 |
Why?
|
Leukemia | 9 | 2024 | 1522 | 0.830 |
Why?
|
Ikaros Transcription Factor | 3 | 2018 | 232 | 0.800 |
Why?
|
Prednisone | 11 | 2018 | 1563 | 0.780 |
Why?
|
Philadelphia Chromosome | 6 | 2023 | 117 | 0.770 |
Why?
|
Disease-Free Survival | 40 | 2024 | 6814 | 0.760 |
Why?
|
Adolescent | 105 | 2024 | 88319 | 0.760 |
Why?
|
Blood Group Antigens | 1 | 2022 | 184 | 0.710 |
Why?
|
Remission Induction | 23 | 2022 | 2396 | 0.690 |
Why?
|
Erwinia | 3 | 2023 | 21 | 0.660 |
Why?
|
Down Syndrome | 3 | 2018 | 901 | 0.630 |
Why?
|
Venous Thromboembolism | 3 | 2024 | 1866 | 0.560 |
Why?
|
Cardiotoxins | 2 | 2013 | 36 | 0.550 |
Why?
|
Prognosis | 44 | 2024 | 29625 | 0.530 |
Why?
|
Gene Expression Regulation, Leukemic | 11 | 2021 | 651 | 0.530 |
Why?
|
Sequence Deletion | 4 | 2018 | 1494 | 0.530 |
Why?
|
Survival Rate | 26 | 2024 | 12725 | 0.520 |
Why?
|
Antibiotic Prophylaxis | 2 | 2018 | 636 | 0.520 |
Why?
|
Pancreatitis | 4 | 2023 | 1096 | 0.510 |
Why?
|
Leukemia, Myeloid, Acute | 15 | 2024 | 3613 | 0.500 |
Why?
|
Razoxane | 6 | 2012 | 43 | 0.490 |
Why?
|
Gene Fusion | 1 | 2018 | 356 | 0.490 |
Why?
|
Humans | 237 | 2024 | 761504 | 0.470 |
Why?
|
Hematopoietic Stem Cell Transplantation | 14 | 2022 | 5671 | 0.460 |
Why?
|
Bacteremia | 2 | 2018 | 979 | 0.460 |
Why?
|
Drug Hypersensitivity | 6 | 2023 | 917 | 0.460 |
Why?
|
Immunotoxins | 3 | 2020 | 175 | 0.460 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2021 | 9280 | 0.440 |
Why?
|
Leukemia, B-Cell | 4 | 2015 | 84 | 0.430 |
Why?
|
Male | 135 | 2024 | 360804 | 0.420 |
Why?
|
Methotrexate | 12 | 2018 | 1719 | 0.420 |
Why?
|
Vincristine | 6 | 2018 | 1036 | 0.410 |
Why?
|
Drug Resistance, Neoplasm | 13 | 2024 | 5305 | 0.410 |
Why?
|
Female | 135 | 2024 | 392644 | 0.410 |
Why?
|
Hemochromatosis | 1 | 2013 | 174 | 0.390 |
Why?
|
Antineoplastic Agents, Hormonal | 4 | 2013 | 1520 | 0.390 |
Why?
|
Antibiotics, Antineoplastic | 6 | 2016 | 678 | 0.390 |
Why?
|
Myeloid-Lymphoid Leukemia Protein | 10 | 2019 | 305 | 0.390 |
Why?
|
Escherichia coli | 6 | 2023 | 4217 | 0.390 |
Why?
|
Blood Transfusion | 2 | 2009 | 1298 | 0.380 |
Why?
|
Clinical Trials, Phase III as Topic | 4 | 2020 | 857 | 0.360 |
Why?
|
Recurrence | 22 | 2024 | 8465 | 0.340 |
Why?
|
Leukocyte Count | 9 | 2018 | 1596 | 0.340 |
Why?
|
Histone-Lysine N-Methyltransferase | 11 | 2019 | 682 | 0.340 |
Why?
|
Proto-Oncogenes | 5 | 2003 | 321 | 0.340 |
Why?
|
Follow-Up Studies | 26 | 2024 | 39106 | 0.330 |
Why?
|
Blast Crisis | 1 | 2009 | 102 | 0.330 |
Why?
|
Chromosome Aberrations | 8 | 2012 | 1768 | 0.330 |
Why?
|
Translocation, Genetic | 10 | 2023 | 1393 | 0.330 |
Why?
|
Treatment Outcome | 46 | 2023 | 64680 | 0.330 |
Why?
|
Protein Kinase Inhibitors | 5 | 2018 | 5671 | 0.330 |
Why?
|
Exotoxins | 2 | 2020 | 121 | 0.320 |
Why?
|
Escherichia coli Proteins | 1 | 2015 | 1067 | 0.310 |
Why?
|
Proto-Oncogene Proteins | 10 | 2019 | 4511 | 0.310 |
Why?
|
Comparative Genomic Hybridization | 3 | 2024 | 473 | 0.310 |
Why?
|
Etoposide | 6 | 2022 | 634 | 0.300 |
Why?
|
Thrombosis | 1 | 2022 | 2942 | 0.300 |
Why?
|
Cognition | 5 | 2016 | 6990 | 0.290 |
Why?
|
Cardiotonic Agents | 5 | 2016 | 539 | 0.280 |
Why?
|
Young Adult | 28 | 2024 | 59243 | 0.280 |
Why?
|
Neoplasm Proteins | 9 | 2019 | 3617 | 0.280 |
Why?
|
Oncogene Proteins, Fusion | 9 | 2023 | 1606 | 0.280 |
Why?
|
Neoplasms, Second Primary | 4 | 2020 | 1052 | 0.270 |
Why?
|
Hematologic Neoplasms | 4 | 2023 | 1896 | 0.270 |
Why?
|
Cell Transformation, Neoplastic | 6 | 2018 | 2825 | 0.260 |
Why?
|
Survivors | 7 | 2016 | 2371 | 0.260 |
Why?
|
Mutation | 17 | 2024 | 30052 | 0.250 |
Why?
|
Gene Rearrangement | 11 | 2022 | 1125 | 0.250 |
Why?
|
Age Factors | 16 | 2020 | 18395 | 0.250 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 4 | 2008 | 164 | 0.240 |
Why?
|
Immunophenotyping | 10 | 2018 | 1870 | 0.240 |
Why?
|
Maximum Tolerated Dose | 4 | 2018 | 883 | 0.240 |
Why?
|
Combined Modality Therapy | 13 | 2020 | 8529 | 0.240 |
Why?
|
Immunotherapy | 2 | 2017 | 4652 | 0.240 |
Why?
|
Polymorphism, Genetic | 5 | 2019 | 4243 | 0.240 |
Why?
|
Neoplastic Stem Cells | 6 | 2024 | 1347 | 0.240 |
Why?
|
Arabinonucleosides | 3 | 2022 | 34 | 0.230 |
Why?
|
Multicenter Studies as Topic | 5 | 2022 | 1702 | 0.230 |
Why?
|
Polymorphism, Single Nucleotide | 11 | 2024 | 15936 | 0.230 |
Why?
|
Apoptosis Regulatory Proteins | 3 | 2014 | 1135 | 0.230 |
Why?
|
Treatment Failure | 6 | 2022 | 2645 | 0.230 |
Why?
|
Calcification, Physiologic | 1 | 2004 | 170 | 0.230 |
Why?
|
Heart Diseases | 2 | 2015 | 2781 | 0.230 |
Why?
|
Central Nervous System Neoplasms | 3 | 2007 | 916 | 0.220 |
Why?
|
Poverty | 3 | 2024 | 2698 | 0.220 |
Why?
|
Risk Assessment | 10 | 2024 | 23995 | 0.220 |
Why?
|
Gels | 1 | 2004 | 420 | 0.220 |
Why?
|
Capillary Leak Syndrome | 2 | 2020 | 34 | 0.220 |
Why?
|
Kaplan-Meier Estimate | 9 | 2018 | 6484 | 0.220 |
Why?
|
Bacterial Toxins | 2 | 2020 | 931 | 0.220 |
Why?
|
BRCA2 Protein | 2 | 2019 | 805 | 0.220 |
Why?
|
Cyclophosphamide | 5 | 2022 | 2218 | 0.210 |
Why?
|
Central Nervous System Diseases | 1 | 2007 | 520 | 0.210 |
Why?
|
Clinical Protocols | 3 | 2011 | 1440 | 0.210 |
Why?
|
Oncogene Protein pp60(v-src) | 2 | 1992 | 75 | 0.210 |
Why?
|
Bone Marrow Cells | 2 | 2009 | 2416 | 0.210 |
Why?
|
Survival Analysis | 13 | 2021 | 10090 | 0.210 |
Why?
|
Stem Cell Transplantation | 4 | 2016 | 1600 | 0.200 |
Why?
|
Glucocorticoids | 5 | 2022 | 2161 | 0.200 |
Why?
|
Infant, Newborn | 21 | 2019 | 26198 | 0.200 |
Why?
|
Receptors, Antigen, T-Cell | 5 | 2019 | 2547 | 0.200 |
Why?
|
Cytogenetics | 3 | 2016 | 198 | 0.200 |
Why?
|
Medical Oncology | 3 | 2020 | 2321 | 0.200 |
Why?
|
Chromosomes, Human, Pair 11 | 4 | 2022 | 410 | 0.200 |
Why?
|
Aminopyridines | 2 | 2016 | 573 | 0.200 |
Why?
|
Transcription Factors | 8 | 2023 | 12128 | 0.200 |
Why?
|
Randomized Controlled Trials as Topic | 8 | 2020 | 10209 | 0.190 |
Why?
|
Apoptosis | 8 | 2022 | 9486 | 0.190 |
Why?
|
Cytarabine | 7 | 2019 | 697 | 0.190 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 6 | 2015 | 359 | 0.190 |
Why?
|
Risk Factors | 27 | 2024 | 74206 | 0.190 |
Why?
|
Sulfonamides | 3 | 2024 | 1978 | 0.190 |
Why?
|
Drug Administration Schedule | 8 | 2014 | 4853 | 0.180 |
Why?
|
Lymphoma | 2 | 2023 | 1901 | 0.180 |
Why?
|
Adenine Nucleotides | 2 | 2011 | 111 | 0.180 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2022 | 2057 | 0.180 |
Why?
|
Adult | 44 | 2024 | 221177 | 0.180 |
Why?
|
Hypertriglyceridemia | 1 | 2023 | 293 | 0.180 |
Why?
|
Pancreatitis, Acute Necrotizing | 1 | 2022 | 173 | 0.170 |
Why?
|
Chromosomes, Human, Pair 21 | 3 | 2015 | 228 | 0.170 |
Why?
|
Hodgkin Disease | 1 | 2008 | 1378 | 0.170 |
Why?
|
Diploidy | 2 | 2019 | 132 | 0.170 |
Why?
|
Gene Duplication | 2 | 2014 | 314 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 5 | 2024 | 1405 | 0.170 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2021 | 3602 | 0.170 |
Why?
|
Chemokine CXCL2 | 1 | 2019 | 106 | 0.170 |
Why?
|
Epigenesis, Genetic | 5 | 2015 | 3802 | 0.170 |
Why?
|
Fractures, Spontaneous | 1 | 2001 | 231 | 0.170 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 7407 | 0.170 |
Why?
|
Duffy Blood-Group System | 1 | 2019 | 58 | 0.170 |
Why?
|
ras Proteins | 1 | 2024 | 1054 | 0.160 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 1 | 2019 | 146 | 0.160 |
Why?
|
Parents | 4 | 2023 | 3563 | 0.160 |
Why?
|
Trypsinogen | 1 | 2018 | 84 | 0.160 |
Why?
|
T-Lymphocytes | 11 | 2023 | 10194 | 0.160 |
Why?
|
Leukemia, Biphenotypic, Acute | 1 | 2018 | 32 | 0.160 |
Why?
|
Membrane Proteins | 5 | 2019 | 7856 | 0.160 |
Why?
|
Bacillus | 1 | 2018 | 78 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2014 | 988 | 0.150 |
Why?
|
Neoplasms | 8 | 2023 | 22170 | 0.150 |
Why?
|
Galectins | 1 | 2021 | 295 | 0.150 |
Why?
|
Nutrition Disorders | 1 | 2019 | 205 | 0.150 |
Why?
|
Neuropsychological Tests | 6 | 2023 | 7045 | 0.150 |
Why?
|
Health Status | 3 | 2021 | 4077 | 0.150 |
Why?
|
Trypsin | 1 | 2018 | 495 | 0.150 |
Why?
|
HMGB Proteins | 1 | 2017 | 45 | 0.150 |
Why?
|
Radiation Tolerance | 2 | 2019 | 479 | 0.150 |
Why?
|
Adenoviruses, Human | 2 | 1989 | 255 | 0.150 |
Why?
|
Immune Evasion | 1 | 2021 | 363 | 0.150 |
Why?
|
Lymphoma, T-Cell | 1 | 2020 | 304 | 0.140 |
Why?
|
Protein Tyrosine Phosphatases | 1 | 2019 | 457 | 0.140 |
Why?
|
Fractures, Bone | 4 | 2024 | 2046 | 0.140 |
Why?
|
Quality of Life | 5 | 2023 | 13367 | 0.140 |
Why?
|
Aspartate-Ammonia Ligase | 2 | 2014 | 18 | 0.140 |
Why?
|
Leukemia, Myeloid | 4 | 2004 | 694 | 0.140 |
Why?
|
Pharmacogenetics | 4 | 2015 | 675 | 0.140 |
Why?
|
Capsid | 2 | 1989 | 435 | 0.140 |
Why?
|
Thymidylate Synthase | 1 | 2016 | 74 | 0.140 |
Why?
|
Infusions, Intravenous | 4 | 2012 | 2219 | 0.140 |
Why?
|
Antigens, CD19 | 1 | 2019 | 424 | 0.140 |
Why?
|
Lysine | 4 | 2014 | 993 | 0.140 |
Why?
|
Time Factors | 15 | 2019 | 39967 | 0.130 |
Why?
|
Cognition Disorders | 4 | 2016 | 3979 | 0.130 |
Why?
|
Myristic Acids | 2 | 1993 | 49 | 0.130 |
Why?
|
Capsid Proteins | 2 | 1989 | 468 | 0.130 |
Why?
|
Executive Function | 2 | 2023 | 1389 | 0.130 |
Why?
|
Retrospective Studies | 24 | 2024 | 80636 | 0.130 |
Why?
|
HIV Seropositivity | 1 | 2002 | 960 | 0.130 |
Why?
|
Injections, Subcutaneous | 4 | 2006 | 681 | 0.130 |
Why?
|
Cataract | 1 | 2022 | 832 | 0.130 |
Why?
|
Troponin T | 3 | 2012 | 780 | 0.130 |
Why?
|
Multivariate Analysis | 5 | 2018 | 12059 | 0.130 |
Why?
|
Polymerase Chain Reaction | 6 | 2016 | 6075 | 0.120 |
Why?
|
Tissue Banks | 1 | 2016 | 184 | 0.120 |
Why?
|
Fusion Proteins, bcr-abl | 4 | 2014 | 431 | 0.120 |
Why?
|
Multidrug Resistance-Associated Proteins | 1 | 2015 | 105 | 0.120 |
Why?
|
Incidence | 11 | 2024 | 21353 | 0.120 |
Why?
|
Health Status Disparities | 2 | 2024 | 1852 | 0.120 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2022 | 1374 | 0.120 |
Why?
|
Genotype | 8 | 2018 | 12990 | 0.120 |
Why?
|
Proportional Hazards Models | 10 | 2022 | 12463 | 0.120 |
Why?
|
Cardiomyopathies | 4 | 2012 | 1964 | 0.120 |
Why?
|
Brain Abscess | 1 | 2015 | 120 | 0.120 |
Why?
|
Burkitt Lymphoma | 3 | 2007 | 335 | 0.120 |
Why?
|
Haploinsufficiency | 2 | 2019 | 337 | 0.120 |
Why?
|
Medication Adherence | 2 | 2016 | 2176 | 0.120 |
Why?
|
Receptors, Cell Surface | 2 | 2019 | 2822 | 0.120 |
Why?
|
Intention to Treat Analysis | 1 | 2015 | 413 | 0.120 |
Why?
|
Mitochondria, Heart | 1 | 2016 | 229 | 0.120 |
Why?
|
Gene Rearrangement, B-Lymphocyte | 2 | 2005 | 111 | 0.120 |
Why?
|
HMGN1 Protein | 1 | 2014 | 27 | 0.120 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2002 | 1085 | 0.120 |
Why?
|
Injections, Intramuscular | 1 | 2015 | 554 | 0.120 |
Why?
|
DNA, Intergenic | 1 | 2014 | 105 | 0.120 |
Why?
|
Genome-Wide Association Study | 4 | 2024 | 12690 | 0.110 |
Why?
|
Gram-Positive Bacterial Infections | 2 | 2015 | 343 | 0.110 |
Why?
|
Hematopoietic Stem Cells | 4 | 2017 | 3396 | 0.110 |
Why?
|
Thrombocytopenia | 1 | 2022 | 1181 | 0.110 |
Why?
|
Injections, Spinal | 3 | 2016 | 318 | 0.110 |
Why?
|
Wilms Tumor | 1 | 2016 | 379 | 0.110 |
Why?
|
INDEL Mutation | 1 | 2014 | 266 | 0.110 |
Why?
|
Genes, src | 1 | 1993 | 51 | 0.110 |
Why?
|
Hypersensitivity | 1 | 2023 | 1171 | 0.110 |
Why?
|
Neutropenia | 1 | 2018 | 885 | 0.110 |
Why?
|
Feasibility Studies | 4 | 2023 | 5247 | 0.110 |
Why?
|
Cell Membrane | 2 | 1993 | 3688 | 0.110 |
Why?
|
Biological Products | 1 | 2022 | 914 | 0.110 |
Why?
|
Hedgehog Proteins | 1 | 2018 | 768 | 0.110 |
Why?
|
Genomic Instability | 1 | 2017 | 709 | 0.110 |
Why?
|
Histones | 3 | 2014 | 2580 | 0.110 |
Why?
|
Purines | 1 | 2016 | 607 | 0.110 |
Why?
|
Gene Deletion | 2 | 2011 | 2665 | 0.110 |
Why?
|
Protein Kinases | 2 | 2018 | 1608 | 0.110 |
Why?
|
Bone Marrow | 7 | 2024 | 2911 | 0.110 |
Why?
|
Orthopedics | 1 | 2022 | 898 | 0.110 |
Why?
|
Receptor Protein-Tyrosine Kinases | 4 | 2004 | 1626 | 0.110 |
Why?
|
Karyotyping | 5 | 2014 | 1171 | 0.110 |
Why?
|
Hyperglycemia | 1 | 2021 | 1376 | 0.110 |
Why?
|
Nutritional Status | 2 | 2019 | 1615 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2014 | 2455 | 0.110 |
Why?
|
Antigens, CD34 | 1 | 2015 | 658 | 0.110 |
Why?
|
Pyrroles | 3 | 2004 | 1125 | 0.110 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2016 | 561 | 0.100 |
Why?
|
Cell Proliferation | 5 | 2017 | 10445 | 0.100 |
Why?
|
bcl-X Protein | 1 | 2014 | 410 | 0.100 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2016 | 592 | 0.100 |
Why?
|
Multigene Family | 2 | 2010 | 1076 | 0.100 |
Why?
|
Anthracyclines | 1 | 2014 | 284 | 0.100 |
Why?
|
Echocardiography | 4 | 2013 | 4989 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-myb | 2 | 2014 | 79 | 0.100 |
Why?
|
Canada | 2 | 2015 | 2122 | 0.100 |
Why?
|
Chromosomes, Human, Pair 1 | 2 | 2010 | 638 | 0.100 |
Why?
|
Histone Deacetylase Inhibitors | 2 | 2015 | 774 | 0.100 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2015 | 705 | 0.100 |
Why?
|
Transplantation, Homologous | 3 | 2020 | 4806 | 0.100 |
Why?
|
Pediatrics | 2 | 2019 | 3589 | 0.100 |
Why?
|
Antioxidants | 1 | 2020 | 1668 | 0.100 |
Why?
|
Janus Kinase 2 | 1 | 2015 | 560 | 0.100 |
Why?
|
Activating Transcription Factors | 1 | 2011 | 30 | 0.100 |
Why?
|
Protein Sorting Signals | 1 | 1992 | 279 | 0.100 |
Why?
|
Anticoagulants | 2 | 2022 | 4812 | 0.100 |
Why?
|
Drugs, Investigational | 1 | 2013 | 212 | 0.100 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2012 | 310 | 0.100 |
Why?
|
RNA Splicing | 2 | 2022 | 918 | 0.100 |
Why?
|
Salvage Therapy | 4 | 2019 | 1264 | 0.090 |
Why?
|
Cardiovascular Agents | 2 | 2010 | 840 | 0.090 |
Why?
|
Cell Line, Tumor | 10 | 2019 | 16981 | 0.090 |
Why?
|
Nutrition Surveys | 1 | 2019 | 1733 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2018 | 10766 | 0.090 |
Why?
|
Indoles | 3 | 2004 | 1833 | 0.090 |
Why?
|
Myeloproliferative Disorders | 2 | 2010 | 613 | 0.090 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3639 | 0.090 |
Why?
|
Genes, T-Cell Receptor gamma | 1 | 2010 | 15 | 0.090 |
Why?
|
Cohort Studies | 14 | 2021 | 41487 | 0.090 |
Why?
|
DNA, Mitochondrial | 1 | 2016 | 865 | 0.090 |
Why?
|
Methylation | 2 | 2014 | 1084 | 0.090 |
Why?
|
Recombinant Fusion Proteins | 2 | 2017 | 3734 | 0.090 |
Why?
|
Benzimidazoles | 1 | 2015 | 858 | 0.090 |
Why?
|
Peptide Fragments | 5 | 2014 | 5112 | 0.080 |
Why?
|
Prospective Studies | 13 | 2023 | 54425 | 0.080 |
Why?
|
Single-Cell Analysis | 1 | 2021 | 2449 | 0.080 |
Why?
|
RNA, Messenger | 6 | 2013 | 12795 | 0.080 |
Why?
|
Lymphoid Enhancer-Binding Factor 1 | 1 | 2010 | 84 | 0.080 |
Why?
|
Codon, Terminator | 1 | 2010 | 124 | 0.080 |
Why?
|
Interdisciplinary Communication | 1 | 2015 | 931 | 0.080 |
Why?
|
Genetic Variation | 2 | 2018 | 6567 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2022 | 2865 | 0.080 |
Why?
|
Antigens, CD | 5 | 2018 | 4003 | 0.080 |
Why?
|
Genetic Counseling | 1 | 2013 | 627 | 0.080 |
Why?
|
Tetrahydrofolate Dehydrogenase | 1 | 2009 | 133 | 0.080 |
Why?
|
Diet | 2 | 2019 | 8075 | 0.080 |
Why?
|
Histone Demethylases | 1 | 2012 | 320 | 0.080 |
Why?
|
Sweet Syndrome | 1 | 2009 | 58 | 0.080 |
Why?
|
International Agencies | 1 | 2009 | 243 | 0.080 |
Why?
|
Clone Cells | 3 | 2024 | 1659 | 0.080 |
Why?
|
Middle Aged | 27 | 2024 | 220895 | 0.080 |
Why?
|
Ventricular Function, Left | 5 | 2015 | 3879 | 0.080 |
Why?
|
International Cooperation | 1 | 2015 | 1422 | 0.080 |
Why?
|
Leukocytes, Mononuclear | 1 | 2016 | 1844 | 0.080 |
Why?
|
Microfilament Proteins | 1 | 2014 | 1134 | 0.080 |
Why?
|
Topotecan | 1 | 2009 | 132 | 0.080 |
Why?
|
Protein-Tyrosine Kinases | 4 | 2004 | 2425 | 0.080 |
Why?
|
DNA-Binding Proteins | 6 | 2023 | 9606 | 0.080 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 1136 | 0.080 |
Why?
|
Nuclear Proteins | 2 | 2014 | 5796 | 0.080 |
Why?
|
Sialoglycoproteins | 1 | 1989 | 315 | 0.080 |
Why?
|
Energy Intake | 1 | 2016 | 2134 | 0.080 |
Why?
|
Behavior | 1 | 2011 | 541 | 0.080 |
Why?
|
Alleles | 6 | 2018 | 6863 | 0.080 |
Why?
|
STAT3 Transcription Factor | 1 | 2012 | 871 | 0.070 |
Why?
|
Enhancer Elements, Genetic | 1 | 2014 | 1363 | 0.070 |
Why?
|
Protein Processing, Post-Translational | 2 | 1993 | 1974 | 0.070 |
Why?
|
Mice | 15 | 2024 | 81525 | 0.070 |
Why?
|
Animals | 23 | 2024 | 168459 | 0.070 |
Why?
|
Gene Rearrangement, T-Lymphocyte | 2 | 2007 | 111 | 0.070 |
Why?
|
Receptor, Notch1 | 2 | 2008 | 496 | 0.070 |
Why?
|
Clinical Trials as Topic | 6 | 2019 | 8002 | 0.070 |
Why?
|
Regression Analysis | 2 | 2011 | 6343 | 0.070 |
Why?
|
Adrenal Cortex Hormones | 2 | 2019 | 1880 | 0.070 |
Why?
|
Alu Elements | 1 | 2007 | 115 | 0.070 |
Why?
|
Bone Marrow Transplantation | 4 | 2014 | 2693 | 0.070 |
Why?
|
Gene Silencing | 2 | 2014 | 1509 | 0.070 |
Why?
|
Gene Expression Regulation, Viral | 1 | 1989 | 439 | 0.070 |
Why?
|
DNA Copy Number Variations | 1 | 2016 | 2020 | 0.070 |
Why?
|
B-Lymphocytes | 5 | 2014 | 4758 | 0.070 |
Why?
|
RNA, Small Interfering | 2 | 2014 | 3429 | 0.070 |
Why?
|
Cell Lineage | 4 | 2024 | 2555 | 0.070 |
Why?
|
Age Distribution | 2 | 2011 | 2880 | 0.070 |
Why?
|
Actins | 1 | 2014 | 2050 | 0.070 |
Why?
|
Ploidies | 1 | 2007 | 285 | 0.070 |
Why?
|
United States | 8 | 2021 | 72334 | 0.070 |
Why?
|
fms-Like Tyrosine Kinase 3 | 5 | 2016 | 495 | 0.070 |
Why?
|
Exons | 3 | 2023 | 2391 | 0.070 |
Why?
|
Disease Progression | 4 | 2021 | 13506 | 0.070 |
Why?
|
Antigens, Differentiation | 1 | 1989 | 910 | 0.070 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2008 | 169 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2016 | 2220 | 0.070 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1336 | 0.060 |
Why?
|
Acute Disease | 7 | 2022 | 7237 | 0.060 |
Why?
|
Base Sequence | 6 | 2014 | 12441 | 0.060 |
Why?
|
Gene Frequency | 3 | 2017 | 3606 | 0.060 |
Why?
|
Cytogenetic Analysis | 3 | 2015 | 270 | 0.060 |
Why?
|
Heart | 2 | 2012 | 4404 | 0.060 |
Why?
|
Neoplasm Staging | 4 | 2013 | 11121 | 0.060 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2017 | 1860 | 0.060 |
Why?
|
Disease Management | 1 | 2016 | 2508 | 0.060 |
Why?
|
Monitoring, Physiologic | 1 | 2013 | 1779 | 0.060 |
Why?
|
HLA Antigens | 1 | 2010 | 1328 | 0.060 |
Why?
|
Flow Cytometry | 5 | 2018 | 5869 | 0.060 |
Why?
|
Gene Expression | 6 | 2016 | 7581 | 0.060 |
Why?
|
Agar | 1 | 2004 | 51 | 0.060 |
Why?
|
Chemical Precipitation | 1 | 2004 | 175 | 0.060 |
Why?
|
Genes, Immunoglobulin | 1 | 2005 | 285 | 0.060 |
Why?
|
Administration, Oral | 3 | 2022 | 4021 | 0.060 |
Why?
|
Haplotypes | 3 | 2019 | 2713 | 0.060 |
Why?
|
Sepharose | 1 | 2004 | 103 | 0.060 |
Why?
|
Signal Transduction | 7 | 2018 | 23445 | 0.060 |
Why?
|
Phenotype | 7 | 2018 | 16591 | 0.060 |
Why?
|
Molecular Sequence Data | 6 | 2014 | 17635 | 0.060 |
Why?
|
Immunoglobulin Joining Region | 1 | 2004 | 37 | 0.060 |
Why?
|
Consensus | 3 | 2022 | 3123 | 0.060 |
Why?
|
Mutation, Missense | 2 | 2011 | 2571 | 0.060 |
Why?
|
Cell-Free System | 1 | 2004 | 340 | 0.060 |
Why?
|
Oxidative Stress | 1 | 2015 | 3113 | 0.060 |
Why?
|
Leukemia, Radiation-Induced | 1 | 2003 | 39 | 0.060 |
Why?
|
Sequence Analysis, RNA | 2 | 2023 | 2020 | 0.060 |
Why?
|
Mice, Inbred NOD | 2 | 2019 | 1827 | 0.060 |
Why?
|
Benzamides | 1 | 2009 | 1370 | 0.050 |
Why?
|
Fatal Outcome | 3 | 2020 | 1834 | 0.050 |
Why?
|
Chromatin | 1 | 2015 | 2960 | 0.050 |
Why?
|
Molecular Targeted Therapy | 3 | 2021 | 2811 | 0.050 |
Why?
|
Myristic Acid | 2 | 1993 | 49 | 0.050 |
Why?
|
Durapatite | 1 | 2004 | 163 | 0.050 |
Why?
|
PTEN Phosphohydrolase | 1 | 2009 | 1115 | 0.050 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2012 | 1723 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2021 | 5840 | 0.050 |
Why?
|
Daunorubicin | 2 | 2019 | 156 | 0.050 |
Why?
|
Mitochondria | 2 | 2018 | 3624 | 0.050 |
Why?
|
Arvicolinae | 2 | 1992 | 21 | 0.050 |
Why?
|
Plant Nectar | 1 | 2022 | 3 | 0.050 |
Why?
|
Leukemia, T-Cell | 1 | 2003 | 101 | 0.050 |
Why?
|
Gelatin | 1 | 2004 | 220 | 0.050 |
Why?
|
Immunoglobulin Variable Region | 1 | 2004 | 419 | 0.050 |
Why?
|
Retinoids | 1 | 2023 | 99 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2023 | 314 | 0.050 |
Why?
|
Diffusion | 1 | 2004 | 814 | 0.050 |
Why?
|
Granulocytes | 1 | 2024 | 551 | 0.050 |
Why?
|
Neoplasm Transplantation | 2 | 2017 | 2016 | 0.050 |
Why?
|
Trisomy | 2 | 1995 | 260 | 0.050 |
Why?
|
Aged | 17 | 2024 | 169289 | 0.050 |
Why?
|
Analysis of Variance | 3 | 2016 | 6228 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 4575 | 0.050 |
Why?
|
Risk | 2 | 2011 | 9610 | 0.050 |
Why?
|
Genetic Association Studies | 3 | 2018 | 2735 | 0.050 |
Why?
|
Protein Biosynthesis | 1 | 1989 | 2113 | 0.050 |
Why?
|
Systems Analysis | 1 | 2023 | 169 | 0.050 |
Why?
|
Janus Kinase 3 | 1 | 2022 | 76 | 0.050 |
Why?
|
Staurosporine | 1 | 2003 | 242 | 0.050 |
Why?
|
Nucleosides | 1 | 2022 | 131 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 7827 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2014 | 8547 | 0.050 |
Why?
|
Drug Synergism | 2 | 2016 | 1755 | 0.050 |
Why?
|
Lymphocyte Activation | 2 | 1989 | 5486 | 0.050 |
Why?
|
Home Nursing | 1 | 2002 | 92 | 0.050 |
Why?
|
Skin Tests | 1 | 2003 | 637 | 0.050 |
Why?
|
Aged, 80 and over | 8 | 2024 | 58976 | 0.050 |
Why?
|
Electromagnetic Fields | 1 | 2003 | 296 | 0.050 |
Why?
|
Chromogranins | 1 | 2022 | 161 | 0.050 |
Why?
|
Blood Cell Count | 1 | 2002 | 397 | 0.050 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 2803 | 0.050 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2004 | 647 | 0.050 |
Why?
|
Zebrafish | 3 | 2018 | 3007 | 0.050 |
Why?
|
Phosphates | 1 | 2004 | 770 | 0.050 |
Why?
|
Pons | 1 | 2022 | 240 | 0.050 |
Why?
|
Lymphoproliferative Disorders | 1 | 2004 | 531 | 0.050 |
Why?
|
Oncogenes | 2 | 2018 | 1222 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2011 | 2986 | 0.040 |
Why?
|
Heart Ventricles | 1 | 2012 | 3807 | 0.040 |
Why?
|
Bacterial Proteins | 1 | 2014 | 3847 | 0.040 |
Why?
|
Quebec | 1 | 2020 | 141 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2003 | 546 | 0.040 |
Why?
|
Recombinant Proteins | 3 | 2016 | 6534 | 0.040 |
Why?
|
GTP-Binding Protein alpha Subunits, Gs | 1 | 2022 | 195 | 0.040 |
Why?
|
Kidney Neoplasms | 1 | 2016 | 4249 | 0.040 |
Why?
|
Vitamin A | 1 | 2023 | 613 | 0.040 |
Why?
|
Cross-Over Studies | 2 | 2005 | 2078 | 0.040 |
Why?
|
Alanine Transaminase | 1 | 2022 | 603 | 0.040 |
Why?
|
Hydrocortisone | 1 | 2007 | 1819 | 0.040 |
Why?
|
Memory Disorders | 2 | 2004 | 1198 | 0.040 |
Why?
|
Monocytes | 2 | 2024 | 2570 | 0.040 |
Why?
|
DNA Mutational Analysis | 3 | 2017 | 4111 | 0.040 |
Why?
|
Mitoxantrone | 1 | 2019 | 148 | 0.040 |
Why?
|
Organizations, Nonprofit | 1 | 2020 | 105 | 0.040 |
Why?
|
DNA Damage | 1 | 2009 | 2446 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 641 | 0.040 |
Why?
|
Fatigue | 2 | 2023 | 1552 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2006 | 6310 | 0.040 |
Why?
|
Internship and Residency | 1 | 2019 | 5880 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 5 | 2019 | 17904 | 0.040 |
Why?
|
Models, Biological | 4 | 2018 | 9469 | 0.040 |
Why?
|
Methylprednisolone | 1 | 2000 | 385 | 0.040 |
Why?
|
Sequence Analysis, DNA | 3 | 2019 | 4740 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2023 | 1699 | 0.040 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 2 | 1992 | 899 | 0.040 |
Why?
|
Immunologic Memory | 1 | 2005 | 1359 | 0.040 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2021 | 467 | 0.040 |
Why?
|
Anemia, Refractory, with Excess of Blasts | 2 | 1995 | 17 | 0.040 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2004 | 612 | 0.040 |
Why?
|
Jurkat Cells | 1 | 2019 | 740 | 0.040 |
Why?
|
Receptors, Antigen, T-Cell, gamma-delta | 1 | 2020 | 347 | 0.040 |
Why?
|
Pilot Projects | 2 | 2023 | 8631 | 0.040 |
Why?
|
Gene Expression Profiling | 4 | 2022 | 9420 | 0.040 |
Why?
|
Myocardial Contraction | 2 | 2015 | 1515 | 0.040 |
Why?
|
Germ Cells | 1 | 2021 | 634 | 0.040 |
Why?
|
Calcium | 4 | 2004 | 5722 | 0.040 |
Why?
|
Pyridines | 1 | 2009 | 2875 | 0.040 |
Why?
|
Research Design | 3 | 2021 | 6180 | 0.040 |
Why?
|
Drug Monitoring | 2 | 2016 | 962 | 0.040 |
Why?
|
Cancer Vaccines | 1 | 2005 | 1051 | 0.040 |
Why?
|
Cells, Cultured | 4 | 2015 | 18965 | 0.030 |
Why?
|
Leukemic Infiltration | 1 | 1997 | 47 | 0.030 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2017 | 106 | 0.030 |
Why?
|
Tumor Cells, Cultured | 2 | 2021 | 6132 | 0.030 |
Why?
|
Body Height | 1 | 2003 | 1570 | 0.030 |
Why?
|
Internet | 2 | 2016 | 3092 | 0.030 |
Why?
|
Radiation Injuries | 1 | 2004 | 1189 | 0.030 |
Why?
|
Alternative Splicing | 1 | 2022 | 1093 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2004 | 1726 | 0.030 |
Why?
|
Hypoalbuminemia | 1 | 2017 | 86 | 0.030 |
Why?
|
Genes, BRCA2 | 1 | 2019 | 601 | 0.030 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2019 | 1693 | 0.030 |
Why?
|
Protein Binding | 3 | 1993 | 9351 | 0.030 |
Why?
|
Anaphylaxis | 1 | 2003 | 757 | 0.030 |
Why?
|
Memory, Short-Term | 1 | 2023 | 982 | 0.030 |
Why?
|
Nurse-Patient Relations | 1 | 2016 | 100 | 0.030 |
Why?
|
Chromatography, Thin Layer | 1 | 2016 | 213 | 0.030 |
Why?
|
Quantitative Trait Loci | 1 | 2024 | 2116 | 0.030 |
Why?
|
Boston | 2 | 2016 | 9326 | 0.030 |
Why?
|
Drug Dosage Calculations | 1 | 2016 | 117 | 0.030 |
Why?
|
Thrombotic Microangiopathies | 1 | 2017 | 123 | 0.030 |
Why?
|
Bacillus cereus | 1 | 2015 | 36 | 0.030 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 225 | 0.030 |
Why?
|
Genes, BRCA1 | 1 | 2019 | 764 | 0.030 |
Why?
|
Neurotoxicity Syndromes | 1 | 2019 | 301 | 0.030 |
Why?
|
DNA | 1 | 2009 | 7212 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2002 | 2571 | 0.030 |
Why?
|
Electron Transport Complex IV | 1 | 2016 | 190 | 0.030 |
Why?
|
Interleukin-2 | 1 | 2002 | 1889 | 0.030 |
Why?
|
Sirolimus | 1 | 2022 | 1533 | 0.030 |
Why?
|
Drug Therapy | 1 | 2018 | 503 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5821 | 0.030 |
Why?
|
Binding Sites | 2 | 2014 | 6055 | 0.030 |
Why?
|
Meninges | 1 | 1997 | 198 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2005 | 1469 | 0.030 |
Why?
|
Benzothiazoles | 1 | 2016 | 247 | 0.030 |
Why?
|
Secondary Prevention | 2 | 2016 | 1475 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2021 | 1188 | 0.030 |
Why?
|
Morbidity | 1 | 2020 | 1750 | 0.030 |
Why?
|
Cytoprotection | 1 | 2015 | 200 | 0.030 |
Why?
|
Counseling | 1 | 2023 | 1547 | 0.030 |
Why?
|
Electron Transport Complex I | 1 | 2016 | 153 | 0.030 |
Why?
|
SEER Program | 1 | 2020 | 1450 | 0.030 |
Why?
|
Ultraviolet Rays | 1 | 2019 | 1080 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2010 | 3778 | 0.030 |
Why?
|
Isoquinolines | 1 | 2016 | 352 | 0.030 |
Why?
|
Amino Acid Sequence | 3 | 2004 | 13446 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2002 | 21012 | 0.030 |
Why?
|
Chromosome Deletion | 2 | 2004 | 1386 | 0.030 |
Why?
|
Fanconi Anemia | 1 | 2016 | 324 | 0.030 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2014 | 114 | 0.030 |
Why?
|
Genes, p53 | 1 | 2016 | 712 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 368 | 0.030 |
Why?
|
Alkylation | 1 | 1993 | 84 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2022 | 2448 | 0.030 |
Why?
|
Transcription, Genetic | 3 | 2018 | 7594 | 0.030 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3688 | 0.030 |
Why?
|
Drug Substitution | 1 | 2016 | 290 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2002 | 1589 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2022 | 26125 | 0.030 |
Why?
|
Stem Cells | 2 | 2024 | 3522 | 0.030 |
Why?
|
Cyclosporine | 1 | 1996 | 778 | 0.030 |
Why?
|
Consensus Sequence | 1 | 1993 | 365 | 0.030 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 529 | 0.030 |
Why?
|
Animals, Genetically Modified | 1 | 2017 | 1561 | 0.030 |
Why?
|
Body Weight | 1 | 2003 | 4618 | 0.030 |
Why?
|
Valproic Acid | 1 | 2015 | 443 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2005 | 4369 | 0.030 |
Why?
|
Delphi Technique | 1 | 2016 | 846 | 0.030 |
Why?
|
Protein Interaction Domains and Motifs | 1 | 2014 | 452 | 0.030 |
Why?
|
Biopsy | 1 | 2024 | 6766 | 0.030 |
Why?
|
DNA, Neoplasm | 1 | 1997 | 1745 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 1989 | 9177 | 0.030 |
Why?
|
Overweight | 1 | 2023 | 2417 | 0.030 |
Why?
|
Chromosome Disorders | 1 | 1995 | 497 | 0.020 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 2014 | 783 | 0.020 |
Why?
|
Nucleoside Transport Proteins | 1 | 2011 | 8 | 0.020 |
Why?
|
Qualitative Research | 1 | 2023 | 3023 | 0.020 |
Why?
|
Odds Ratio | 2 | 2017 | 9646 | 0.020 |
Why?
|
RNA | 1 | 2022 | 2726 | 0.020 |
Why?
|
Acetylation | 1 | 2014 | 1055 | 0.020 |
Why?
|
Cell Compartmentation | 1 | 1992 | 384 | 0.020 |
Why?
|
Binding, Competitive | 1 | 1993 | 1141 | 0.020 |
Why?
|
Phosphorylation | 3 | 2016 | 8320 | 0.020 |
Why?
|
Metabolomics | 1 | 2021 | 1659 | 0.020 |
Why?
|
Subcellular Fractions | 1 | 1992 | 532 | 0.020 |
Why?
|
Phosphatidylinositols | 2 | 1989 | 282 | 0.020 |
Why?
|
Random Allocation | 1 | 2016 | 2395 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2005 | 4580 | 0.020 |
Why?
|
Homeodomain Proteins | 3 | 2008 | 2416 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 1992 | 867 | 0.020 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 1992 | 386 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2019 | 1858 | 0.020 |
Why?
|
Health Literacy | 1 | 2016 | 444 | 0.020 |
Why?
|
Denmark | 1 | 2013 | 771 | 0.020 |
Why?
|
Linear Models | 2 | 2016 | 5871 | 0.020 |
Why?
|
Gene Amplification | 1 | 2015 | 1089 | 0.020 |
Why?
|
Promoter Regions, Genetic | 2 | 2014 | 5789 | 0.020 |
Why?
|
Homozygote | 1 | 2015 | 1776 | 0.020 |
Why?
|
Diffusion of Innovation | 1 | 2015 | 728 | 0.020 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2011 | 295 | 0.020 |
Why?
|
Nucleosomes | 1 | 2014 | 487 | 0.020 |
Why?
|
Genetic Testing | 3 | 2015 | 3537 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2015 | 856 | 0.020 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1995 | 686 | 0.020 |
Why?
|
Lipids | 1 | 2021 | 3341 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2016 | 1386 | 0.020 |
Why?
|
Polyribosomes | 1 | 1989 | 109 | 0.020 |
Why?
|
Standard of Care | 1 | 2013 | 551 | 0.020 |
Why?
|
Ionophores | 1 | 1989 | 107 | 0.020 |
Why?
|
Cancer Care Facilities | 1 | 2012 | 422 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2016 | 2231 | 0.020 |
Why?
|
DNA Primers | 1 | 2014 | 2819 | 0.020 |
Why?
|
Cisplatin | 1 | 1996 | 1651 | 0.020 |
Why?
|
Permeability | 1 | 2011 | 723 | 0.020 |
Why?
|
Up-Regulation | 1 | 2018 | 4124 | 0.020 |
Why?
|
Cross-Linking Reagents | 1 | 1992 | 687 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2007 | 2510 | 0.020 |
Why?
|
Puerto Rico | 1 | 2010 | 376 | 0.020 |
Why?
|
History, 21st Century | 1 | 2015 | 1567 | 0.020 |
Why?
|
Predictive Value of Tests | 3 | 2015 | 15266 | 0.020 |
Why?
|
Zinc Fingers | 1 | 2011 | 579 | 0.020 |
Why?
|
Medical Records | 2 | 2007 | 1408 | 0.020 |
Why?
|
Carcinoma, Transitional Cell | 1 | 1996 | 782 | 0.020 |
Why?
|
Protein Methyltransferases | 1 | 2008 | 53 | 0.020 |
Why?
|
DNA Methylation | 2 | 2014 | 4398 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1993 | 2748 | 0.020 |
Why?
|
Precipitin Tests | 1 | 1989 | 814 | 0.020 |
Why?
|
Body Mass Index | 2 | 2023 | 12953 | 0.020 |
Why?
|
Sequence Alignment | 1 | 1993 | 2180 | 0.020 |
Why?
|
Mice, Transgenic | 2 | 2014 | 9539 | 0.020 |
Why?
|
Second Messenger Systems | 1 | 1989 | 202 | 0.020 |
Why?
|
Heterozygote | 1 | 2015 | 2787 | 0.020 |
Why?
|
Communication | 1 | 2023 | 3873 | 0.020 |
Why?
|
Fetal Blood | 1 | 2015 | 1347 | 0.020 |
Why?
|
Quinolines | 1 | 2014 | 764 | 0.020 |
Why?
|
Age of Onset | 1 | 2015 | 3305 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2015 | 1505 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3358 | 0.020 |
Why?
|
Pain | 1 | 2023 | 5073 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2023 | 4481 | 0.020 |
Why?
|
Biological Transport | 1 | 1992 | 2091 | 0.020 |
Why?
|
Histiocytosis, Sinus | 1 | 2008 | 45 | 0.020 |
Why?
|
Imidazoles | 1 | 2014 | 1180 | 0.020 |
Why?
|
Base Pairing | 1 | 2008 | 140 | 0.020 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2011 | 617 | 0.020 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2011 | 621 | 0.020 |
Why?
|
Head and Neck Neoplasms | 1 | 2002 | 2895 | 0.020 |
Why?
|
History, 20th Century | 1 | 2015 | 2767 | 0.020 |
Why?
|
Blood Glucose | 1 | 2021 | 6391 | 0.020 |
Why?
|
Insulin | 1 | 2021 | 6596 | 0.020 |
Why?
|
Weight Gain | 1 | 2017 | 2348 | 0.020 |
Why?
|
Structure-Activity Relationship | 1 | 1992 | 3076 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2011 | 1171 | 0.020 |
Why?
|
Memory | 1 | 2016 | 2188 | 0.020 |
Why?
|
Spironolactone | 1 | 2010 | 412 | 0.020 |
Why?
|
Neprilysin | 1 | 2009 | 478 | 0.020 |
Why?
|
Linkage Disequilibrium | 1 | 2011 | 1998 | 0.020 |
Why?
|
Carcinoma, Merkel Cell | 1 | 1991 | 328 | 0.020 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2002 | 4026 | 0.020 |
Why?
|
Family Health | 1 | 2011 | 1257 | 0.020 |
Why?
|
Integrases | 1 | 2008 | 516 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 2007 | 1302 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2016 | 1943 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2016 | 2319 | 0.020 |
Why?
|
Attention | 1 | 2016 | 2396 | 0.020 |
Why?
|
Proteome | 1 | 2016 | 1862 | 0.020 |
Why?
|
Sepsis | 1 | 2000 | 2585 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2008 | 855 | 0.020 |
Why?
|
Hematopoiesis | 1 | 2015 | 2049 | 0.020 |
Why?
|
Blotting, Western | 1 | 2013 | 5035 | 0.020 |
Why?
|
Thymopoietins | 1 | 2005 | 10 | 0.020 |
Why?
|
Methyltransferases | 1 | 2008 | 377 | 0.020 |
Why?
|
Registries | 1 | 2002 | 8224 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2008 | 943 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2523 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2012 | 1722 | 0.020 |
Why?
|
Ganglioneuroblastoma | 1 | 1964 | 10 | 0.020 |
Why?
|
Cell Communication | 1 | 1992 | 1657 | 0.010 |
Why?
|
Cytoskeleton | 1 | 1989 | 1170 | 0.010 |
Why?
|
Prevalence | 1 | 2021 | 15732 | 0.010 |
Why?
|
Biological Availability | 1 | 2005 | 390 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2014 | 22169 | 0.010 |
Why?
|
Ganglioneuroma | 1 | 1964 | 53 | 0.010 |
Why?
|
Drug Combinations | 1 | 2010 | 2048 | 0.010 |
Why?
|
Ventricular Remodeling | 1 | 2012 | 1267 | 0.010 |
Why?
|
Telemedicine | 1 | 2002 | 3051 | 0.010 |
Why?
|
Central Nervous System | 2 | 2002 | 1336 | 0.010 |
Why?
|
VDJ Recombinases | 1 | 2004 | 84 | 0.010 |
Why?
|
Half-Life | 1 | 2005 | 651 | 0.010 |
Why?
|
Stem Cell Factor | 1 | 2004 | 195 | 0.010 |
Why?
|
Ranitidine | 1 | 2003 | 34 | 0.010 |
Why?
|
Antipruritics | 1 | 2003 | 31 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2009 | 1380 | 0.010 |
Why?
|
Chromosome Breakage | 1 | 2004 | 159 | 0.010 |
Why?
|
Carcinogenicity Tests | 1 | 2003 | 38 | 0.010 |
Why?
|
Diphenhydramine | 1 | 2003 | 63 | 0.010 |
Why?
|
Catecholamines | 1 | 1964 | 386 | 0.010 |
Why?
|
HeLa Cells | 1 | 1989 | 3093 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1996 | 2223 | 0.010 |
Why?
|
Case-Control Studies | 2 | 2012 | 22176 | 0.010 |
Why?
|
Metabolism | 1 | 1964 | 193 | 0.010 |
Why?
|
Protein Kinase C | 2 | 2003 | 1202 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2016 | 3249 | 0.010 |
Why?
|
Recombination, Genetic | 1 | 2007 | 1519 | 0.010 |
Why?
|
Pharmacokinetics | 1 | 2003 | 86 | 0.010 |
Why?
|
Annexin A5 | 1 | 2003 | 103 | 0.010 |
Why?
|
Dimerization | 1 | 2004 | 891 | 0.010 |
Why?
|
Bone Marrow Examination | 1 | 2003 | 154 | 0.010 |
Why?
|
Aspartic Acid Endopeptidases | 1 | 2004 | 311 | 0.010 |
Why?
|
Receptors, Natural Killer Cell | 1 | 2002 | 57 | 0.010 |
Why?
|
Chelating Agents | 1 | 2004 | 387 | 0.010 |
Why?
|
Frameshift Mutation | 1 | 2004 | 392 | 0.010 |
Why?
|
Chromosomes, Human, X | 1 | 2004 | 321 | 0.010 |
Why?
|
Cyclosporins | 1 | 2002 | 216 | 0.010 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2002 | 95 | 0.010 |
Why?
|
Life Tables | 1 | 2002 | 364 | 0.010 |
Why?
|
Histamine H2 Antagonists | 1 | 2003 | 166 | 0.010 |
Why?
|
Anti-Allergic Agents | 1 | 2003 | 153 | 0.010 |
Why?
|
Urticaria | 1 | 2003 | 150 | 0.010 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2003 | 375 | 0.010 |
Why?
|
Brunner Glands | 1 | 1961 | 11 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2017 | 14666 | 0.010 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2003 | 350 | 0.010 |
Why?
|
Computer Systems | 1 | 2003 | 470 | 0.010 |
Why?
|
Sex Factors | 1 | 2016 | 10552 | 0.010 |
Why?
|
Data Collection | 1 | 2011 | 3322 | 0.010 |
Why?
|
Norepinephrine | 1 | 1964 | 897 | 0.010 |
Why?
|
Interleukin-3 | 1 | 2003 | 425 | 0.010 |
Why?
|
Stroke Volume | 1 | 2015 | 5496 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2003 | 882 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2003 | 748 | 0.010 |
Why?
|
Patient Selection | 1 | 2013 | 4244 | 0.010 |
Why?
|
Antigen-Presenting Cells | 1 | 2005 | 964 | 0.010 |
Why?
|
Pathology | 1 | 1964 | 270 | 0.010 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2003 | 535 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 12947 | 0.010 |
Why?
|
RNA, Viral | 1 | 1989 | 2846 | 0.010 |
Why?
|
Area Under Curve | 1 | 2005 | 1638 | 0.010 |
Why?
|
Protease Inhibitors | 1 | 2004 | 754 | 0.010 |
Why?
|
Epinephrine | 1 | 1964 | 792 | 0.010 |
Why?
|
Likelihood Functions | 1 | 2004 | 992 | 0.010 |
Why?
|
Endopeptidases | 1 | 2004 | 774 | 0.010 |
Why?
|
Adenomatous Polyps | 1 | 1961 | 108 | 0.010 |
Why?
|
Endothelial Growth Factors | 1 | 2003 | 673 | 0.010 |
Why?
|
Genes, Homeobox | 1 | 2001 | 285 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 1996 | 4234 | 0.010 |
Why?
|
Genetic Heterogeneity | 1 | 2004 | 732 | 0.010 |
Why?
|
Drug Eruptions | 1 | 2003 | 335 | 0.010 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2004 | 620 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2012 | 3826 | 0.010 |
Why?
|
Pruritus | 1 | 2003 | 380 | 0.010 |
Why?
|
Lymphokines | 1 | 2003 | 927 | 0.010 |
Why?
|
Polyps | 1 | 1961 | 200 | 0.010 |
Why?
|
Nausea | 1 | 2002 | 679 | 0.010 |
Why?
|
Point Mutation | 1 | 2004 | 1595 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20098 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2001 | 750 | 0.010 |
Why?
|
Cell Differentiation | 2 | 2008 | 11528 | 0.010 |
Why?
|
Necrosis | 1 | 2003 | 1611 | 0.010 |
Why?
|
Hematologic Diseases | 1 | 2002 | 496 | 0.010 |
Why?
|
Duodenum | 1 | 1961 | 490 | 0.010 |
Why?
|
Leucovorin | 1 | 2000 | 643 | 0.010 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2000 | 238 | 0.010 |
Why?
|
MicroRNAs | 1 | 2014 | 3816 | 0.010 |
Why?
|
Models, Genetic | 1 | 2007 | 3442 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2004 | 3792 | 0.010 |
Why?
|
Ultrasonography | 1 | 2010 | 5972 | 0.010 |
Why?
|
Dopamine | 1 | 1964 | 1607 | 0.010 |
Why?
|
Down-Regulation | 1 | 2004 | 2919 | 0.010 |
Why?
|
Cell Cycle | 1 | 2004 | 2932 | 0.010 |
Why?
|
Receptors, Immunologic | 1 | 2002 | 1410 | 0.010 |
Why?
|
Europe | 1 | 2003 | 3422 | 0.010 |
Why?
|
Neuroblastoma | 1 | 1964 | 1250 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2002 | 3416 | 0.010 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2003 | 1651 | 0.010 |
Why?
|
Cell Line | 1 | 1989 | 15601 | 0.010 |
Why?
|
Transfection | 1 | 2003 | 5774 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18252 | 0.010 |
Why?
|
Enzyme Activation | 2 | 1992 | 3597 | 0.010 |
Why?
|
Ovarian Neoplasms | 1 | 2011 | 4876 | 0.010 |
Why?
|
Vinblastine | 1 | 1996 | 488 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2009 | 12974 | 0.010 |
Why?
|
Mortality | 1 | 2005 | 2901 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2011 | 5146 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2002 | 2200 | 0.010 |
Why?
|
Educational Measurement | 1 | 2000 | 1254 | 0.010 |
Why?
|
Radiation Dosage | 1 | 2001 | 1958 | 0.010 |
Why?
|
Stress, Physiological | 1 | 2000 | 1403 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-fyn | 1 | 1992 | 110 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2003 | 3492 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2013 | 9031 | 0.010 |
Why?
|
Type C Phospholipases | 1 | 1992 | 287 | 0.010 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 1992 | 283 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1991 | 5821 | 0.010 |
Why?
|
Receptors, Interleukin-2 | 1 | 1992 | 562 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2009 | 15842 | 0.010 |
Why?
|
Postoperative Period | 1 | 1996 | 1813 | 0.010 |
Why?
|
Zidovudine | 1 | 1992 | 624 | 0.010 |
Why?
|
Ionomycin | 1 | 1989 | 110 | 0.010 |
Why?
|
Ethers | 1 | 1989 | 73 | 0.010 |
Why?
|
Logistic Models | 1 | 2004 | 13255 | 0.010 |
Why?
|
Mitogens | 1 | 1989 | 230 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell, alpha-beta | 1 | 1992 | 800 | 0.000 |
Why?
|
Hydrolysis | 1 | 1989 | 664 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 36426 | 0.000 |
Why?
|
Cholecalciferol | 1 | 1992 | 553 | 0.000 |
Why?
|
Isoenzymes | 1 | 1992 | 1687 | 0.000 |
Why?
|
Flowmeters | 1 | 1946 | 6 | 0.000 |
Why?
|
Vital Capacity | 1 | 1946 | 971 | 0.000 |
Why?
|
Cell Division | 1 | 1989 | 4465 | 0.000 |
Why?
|
Kidney | 1 | 1996 | 7048 | 0.000 |
Why?
|
Neoplasm Metastasis | 1 | 1991 | 4915 | 0.000 |
Why?
|